Navigation Links
Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
Date:3/9/2009

TUSTIN, Calif., March 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that senior management will present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 am EDT at the Boston Marriott Copley Place.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at www.peregrineinc.com. The archived replay will be available for approximately 30 days following the presentation.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                 Media
    info@peregrineinc.com                     Barbara Lindheim
    (800) 987-8256                            (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
4. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
5. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
8. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
9. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
11. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Dr. Asher Kimchi, Founder and Chairman of the International ... at the 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. In ... Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. Elefteriades ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
(Date:7/18/2017)... ... , ... Sourcing custom glass or quartz parts can be a daunting task. ... execute your job can take many hours of emails, phone calls and on-line research. ... showcase the company’s capabilities and core custom categories, and enables you to start the ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation won the 2017 ... of the Allotrope Framework for commercial use. , The Bio-IT World Best Practices ... elevate the critical role of information technology in modern biomedical research, but also ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):